Payment overview · 2025
General Payments
$1,129.90
65 reported records · 17 companies
Healthcare provider profile · identity verified
Benjamin D Keeley, MD
Allopathic & Osteopathic Physicians|Family Medicine · OWENSBORO, KY · NPI 1881694545
Verified facts
What the public records show
CMS Open Payments records show Benjamin D Keeley, MD received $1,129.90 in general payments during 2025 across 65 reported records.
Novo Nordisk Inc accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 426 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $220.21 | 19.5% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $158.90 | 14.1% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.68 | 8.7% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $79.86 | 7.1% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.07 | 6.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.03 | 6.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $64.55 | 5.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.58 | 5.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.88 | 4.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.98 | 4.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.91 | 4.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.56 | 4.0% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $34.18 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.66 | 2.6% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.38 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.93 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.54 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,129.90 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $170.75 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $135.74 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $112.99 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.99 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $80.48 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $79.86 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $77.07 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.95 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.95 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.58 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.98 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.91 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $45.91 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.56 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.38 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
426 | 55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 836 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 830 | 129 |
| Furosemide | Furosemide | 789 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 640 | 132 |
| Lisinopril | Lisinopril | 624 | 142 |
| Potassium Chloride | Potassium Chloride | 600 | 130 |
| Alprazolam | Alprazolam | 511 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 509 | 111 |
| Sertraline Hcl | Sertraline Hcl | 490 | 88 |
| Omeprazole | Omeprazole | 477 | 113 |
| Gabapentin | Gabapentin | 460 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 104 |
| Eliquis | Apixaban | 426 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 393 | 94 |
| Losartan Potassium | Losartan Potassium | 391 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 374 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 88 |
| Metformin Hcl | Metformin Hcl | 323 | 77 |
| Simvastatin | Simvastatin | 311 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 288 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 272 | 67 |
| Famotidine | Famotidine | 258 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 256 | 36 |
| Atenolol | Atenolol | 219 | 48 |
| Carvedilol | Carvedilol | 217 | 40 |
| Montelukast Sodium | Montelukast Sodium | 207 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 197 | 44 |
| Clonazepam | Clonazepam | 178 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 41 |
| Trazodone Hcl | Trazodone Hcl | 171 | 41 |
| Warfarin Sodium | Warfarin Sodium | 170 | 14 |
| Allopurinol | Allopurinol | 168 | 36 |
| Buspirone Hcl | Buspirone Hcl | 160 | 29 |
| Tramadol Hcl | Tramadol Hcl | 160 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 155 | 19 |
| Pregabalin | Pregabalin | 145 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 38 |
| Glipizide Er | Glipizide | 137 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 40 |
| Lorazepam | Lorazepam | 124 | 35 |
| Ozempic | Semaglutide | 123 | 21 |
| Estradiol | Estradiol | 120 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 120 | 26 |
| Prednisone | Prednisone | 114 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 17 |
| Nifedipine Er | Nifedipine | 108 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 108 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 22 |
| Sucralfate | Sucralfate | 103 | 15 |
| Lovastatin | Lovastatin | 102 | 23 |
| Donepezil Hcl | Donepezil Hcl | 101 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 35 |
| Mirtazapine | Mirtazapine | 96 | 21 |
| Novolog Flexpen | Insulin Aspart | 96 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 26 |
| Jardiance | Empagliflozin | 91 | 12 |
| Memantine Hcl | Memantine Hcl | 89 | 19 |
| Nystatin | Nystatin | 89 | 25 |
| Cephalexin | Cephalexin | 85 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 15 |
| Spironolactone | Spironolactone | 82 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 30 |
| Cefuroxime | Cefuroxime Axetil | 75 | 53 |
| Dicyclomine Hcl | Dicyclomine Hcl | 75 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 23 |
| Diazepam | Diazepam | 74 | 13 |
| Ondansetron Odt | Ondansetron | 72 | 29 |
| Januvia | Sitagliptin Phosphate | 69 | suppressed |
| Digoxin | Digoxin | 68 | 14 |
| Entresto | Sacubitril/Valsartan | 68 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 65 | 15 |
| Farxiga | Dapagliflozin Propanediol | 63 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 11 |
| Gemtesa | Vibegron | 61 | suppressed |
| Azithromycin | Azithromycin | 58 | 27 |
| Synthroid | Levothyroxine Sodium | 56 | 16 |
| Colesevelam Hcl | Colesevelam Hcl | 54 | suppressed |
| Ezetimibe | Ezetimibe | 54 | 11 |
| Aripiprazole | Aripiprazole | 53 | 13 |
| Chlorthalidone | Chlorthalidone | 53 | 12 |
| Propranolol Hcl | Propranolol Hcl | 53 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Methocarbamol | Methocarbamol | 52 | 17 |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | suppressed |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Bumetanide | Bumetanide | 47 | suppressed |
| Finasteride | Finasteride | 47 | 12 |
| Galantamine Hbr | Galantamine Hbr | 47 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 46 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | suppressed |
| Topiramate | Topiramate | 46 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 14 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 13 |
| Fluconazole | Fluconazole | 43 | 31 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 42 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 19 |
| Glipizide | Glipizide | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 26 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 12 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 37 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 36 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 21 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | suppressed |
| Niacin Er | Niacin | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 27 | suppressed |
| Nystop | Nystatin | 27 | 13 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Linzess | Linaclotide | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Scopolamine | Scopolamine | 26 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Hydrocortisone | Hydrocortisone | 24 | 13 |
| Klayesta | Nystatin | 24 | 14 |
| Cinacalcet Hcl | Cinacalcet Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Lactulose | Lactulose | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | 11 |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nateglinide | Nateglinide | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Symproic | Naldemedine Tosylate | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,129.90 · 65 records | Novo Nordisk Inc | ABRYSVO, AREXVY, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error